ArticleJournal of managed care & specialty pharmacy2021
Cost-utility analysis of treatment options after initial tumor necrosis factor inhibitor therapy discontinuation in patients with rheumatoid arthritis.
Aliza R Karpes Matusevich, Lincy S Lai, Wenyaw Chan, J Michael Swint, Scott B Cantor, Maria E Suarez-Almazor, Maria A Lopez-Olivo
Open access · bronzeAbstract read
In one paragraphArticle in Journal of managed care & specialty pharmacy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 3 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
7 authors at 2 institutions in 1 country.
Aliza R Karpes MatusevichDepartment of Management, Policy and Community Health, School of Public Health, The University of Texas Health Science Center at Houston.
Lincy S LaiDepartment of Management, Policy and Community Health, School of Public Health, The University of Texas Health Science Center at Houston.
Wenyaw ChanDepartment of Biostatistics and Data Science, School of Public Health, and Center for Clinical Research and Evidence-Based Medicine, McGovern School of Medicine, The University of Texas Health Science Center at Houston.
J Michael SwintDepartment of Management, Policy and Community Health, School of Public Health, and Center for Clinical Research and Evidence-Based Medicine, McGovern School of Medicine, The University of Texas Health Science Center at Houston.
Scott B CantorDepartment of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston.
Maria E Suarez-AlmazorDepartment of Health Services Research and Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston.
Maria A Lopez-OlivoDepartment of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston.
The University of Texas Health Science Center at Houston · USThe University of Texas MD Anderson Cancer Center · US
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Cost-Benefit AnalysisMedication AdherencePatient Acceptance of Health CareAbataceptAdalimumabAdolescentAdultAgedAged, 80 and overAntirheumatic AgentsArthritis, RheumatoidFemaleHumansInsurance Claim ReviewMaleMiddle AgedAbataceptAdalimumabAntirheumatic AgentsTumor Necrosis Factor-alpha
Identifiers
PMID33377443
PMCPMC10391179
OpenAlexW3116415603
What OpenQuestion holds
Textmetadata
Read underepoch 390